Article

Macugen approval process moves forward

Eyetech Pharmaceuticals Inc. and Pfizer Inc. have filed a new drug application with the FDA for the 0.3 mg dose of pegaptanib sodium injection (Macugen) as a treatment for AMD (also see Page 46 in this issue).

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
New study highlights retinopathy risk from hair dye use
December 9th 2024

New study highlights retinopathy risk from hair dye use

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study finds increased air pollution leads to surge in daily eye clinic visits
December 9th 2024

Study finds increased air pollution leads to surge in daily eye clinic visits

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Study highlights current and potential roles of AI in glaucoma diagnosis
December 7th 2024

Study highlights current and potential roles of AI in glaucoma diagnosis

Study: CRVO patients face higher heart attack risk
December 7th 2024

Study: CRVO patients face higher heart attack risk

© 2024 MJH Life Sciences

All rights reserved.